Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas V Faller

Showing results (111-120 of 126) with videos related to

Pageof 13
Sort By:
American Journal of Hematology|January 28, 2023
Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choiceVaishali Sanchorawala, Ashutosh D Wechalekar, Kihyun Kim, et al.
Science Signaling|September 3, 2015
The E3 ligase APC/C(Cdh1) promotes ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growthJuxiang Cao, Xiangpeng Dai, Lixin Wan, et al.
Bioresearch Open Access|April 8, 2020
Klotho Pathways, Myelination Disorders, Neurodegenerative Diseases, and Epigenetic DrugsWalter H Moos, Douglas V Faller, Ioannis P Glavas, et al.
Leukemia & Lymphoma|November 28, 2024
Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemiaNicholas J Short, Agnieszka Wierzbowska, Thomas Cluzeau, et al.
The Lancet. Haematology|June 2, 2024
Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding studyOlga Salamero, Antonieta Molero, José Antonio Pérez-Simón, et al.
Leukemia|November 18, 2021
Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AMLMikkael A Sekeres, Justin Watts, Atanas Radinoff, et al.
Gynecologic Oncology|October 15, 2023
A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancerSileny N Han, Amit Oza, Nicoletta Colombo, et al.
Biochemical Pharmacology|October 21, 2021
Pathogenic mitochondrial dysfunction and metabolic abnormalitiesWalter H Moos, Douglas V Faller, Ioannis P Glavas, et al.
Leukemia|January 23, 2021
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AMLMikkael A Sekeres, Justin Watts, Atanas Radinoff, et al.
Biochemical Pharmacology|July 14, 2022
Treatment and prevention of pathological mitochondrial dysfunction in retinal degeneration and in photoreceptor injuryWalter H Moos, Douglas V Faller, Ioannis P Glavas, et al.
Pageof 13

Showing results (111-120 of 126) with videos related to

Sort By:
Pageof 13
American Journal of Hematology|January 28, 2023
Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choiceVaishali Sanchorawala, Ashutosh D Wechalekar, Kihyun Kim, et al.
Science Signaling|September 3, 2015
The E3 ligase APC/C(Cdh1) promotes ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growthJuxiang Cao, Xiangpeng Dai, Lixin Wan, et al.
Bioresearch Open Access|April 8, 2020
Klotho Pathways, Myelination Disorders, Neurodegenerative Diseases, and Epigenetic DrugsWalter H Moos, Douglas V Faller, Ioannis P Glavas, et al.
Leukemia & Lymphoma|November 28, 2024
Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemiaNicholas J Short, Agnieszka Wierzbowska, Thomas Cluzeau, et al.
The Lancet. Haematology|June 2, 2024
Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding studyOlga Salamero, Antonieta Molero, José Antonio Pérez-Simón, et al.
Leukemia|November 18, 2021
Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AMLMikkael A Sekeres, Justin Watts, Atanas Radinoff, et al.
Gynecologic Oncology|October 15, 2023
A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancerSileny N Han, Amit Oza, Nicoletta Colombo, et al.
Biochemical Pharmacology|October 21, 2021
Pathogenic mitochondrial dysfunction and metabolic abnormalitiesWalter H Moos, Douglas V Faller, Ioannis P Glavas, et al.
Leukemia|January 23, 2021
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AMLMikkael A Sekeres, Justin Watts, Atanas Radinoff, et al.
Biochemical Pharmacology|July 14, 2022
Treatment and prevention of pathological mitochondrial dysfunction in retinal degeneration and in photoreceptor injuryWalter H Moos, Douglas V Faller, Ioannis P Glavas, et al.
Pageof 13